This website uses cookies to improve your experience.

Cookie policy

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.


Perez-Garcia JM, Cortes J, Ruiz-Borrego M Colleoni M, Stradella A, Bermejo B et al, on behalf of PHERGain Trial Investigators.

Lancet 2024; 403: 1649-1659.

This complex study that included 356 patients with HER2 +ve breast cancer with visible disease on PET imaging showed that around one third of patients could avoid chemotherapy and just have immunotherapy and hormonal treatment, with similar three-year survival rates.

Comment: Research that reduces the need for chemotherapy is always welcome, and refines the treatment pathway.

Read paper

Academy


Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.

The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.

Discover the Academy
Surgeon Training & Surgeons in Surgery